You
IB

Innexus Biotechnology Inc

Company · Health · A1
Statements1
Sightings1
Years covered2007 – now
Primary sourceSEC Form 20-F
All statements
2007 – nowCurrentOur mission is to become the leader in the development of a new generation of DXL™ -modified monoclonal antibodies that have significantly improved therapeutic potency and novel properties over un-modified monoclonal antibodies.Mission · Market leadership · SEC Form 20-F, filed 2007-12-26
Organization
Type
Company
Industry
Health
Location
A1, US
Size
—
Website
—
Status
active
All filings on SEC EDGAR ↗